Sensitivity of SARS-CoV-2 antibody tests with late convalescent sera.
Antibody test
CMIA, chemiluminescence microparticle immuno-assay
COVID-19
COVID-19, Corona-virus disease 2019
ECLIA, electrochemiluminescence immunoassay
ELISA, enzyme immunoassay
Late convalescent sera
MIA, microparticle immunoassay
N, nucleoprotein
RBD, receptor binding domain
SARS-CoV-2, Severe acute respiratory syndrome coronavirus-2
Sensitivity
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Journal
Journal of clinical virology plus
ISSN: 2667-0380
Titre abrégé: J Clin Virol Plus
Pays: England
ID NLM: 9918283581506676
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
03
03
2021
revised:
23
07
2021
accepted:
16
08
2021
entrez:
9
3
2022
pubmed:
10
3
2022
medline:
10
3
2022
Statut:
ppublish
Résumé
SARS-CoV-2-specific IgM antibodies wane during the first three months after infection and IgG antibody levels decline. This may limit the ability of antibody tests to identify previous SARS-CoV-2 infection at later time points. To examine if the diagnostic sensitivity of antibody tests falls off, we compared the sensitivity of two nucleoprotein-based antibody tests, the Roche Elecsis II Anti-SARS-CoV-2 and the Abbott SARS-CoV-2 IgG assay and three glycoprotein-based tests, the Abbott SARS-CoV-2 IgG II Quant, Siemens Atellica IM COV2T and Euroimmun SARS-CoV-2 assay with 53 sera obtained 6 months after SARS-CoV-2 infection. The sensitivity of the Roche, Abbott SARS-CoV-2 IgG II Quant and Siemens antibody assays was 94.3% (95% confidence interval (CI) 84.3-98.8%), 98.1 % (95% CI: 89.9-100%) and 100 % (95% CI: 93.3-100%). The sensitivity of the N-based Abbott SARS-CoV-2 IgG and the glycoprotein-based Euroimmun ELISA was 45.3 % (95% CI: 31.6-59.6%) and 83.3% (95% CI: 70.2-91.9%). The nucleoprotein-based Roche and the glycoprotein-based Abbott receptor binding domain (RBD) and Siemens tests were more sensitive than the N-based Abbott and the Euroimmun antibody tests (
Identifiants
pubmed: 35262021
doi: 10.1016/j.jcvp.2021.100038
pii: S2667-0380(21)00030-2
pmc: PMC8372433
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100038Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interests.
Références
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10208-10218
pubmed: 33090430
Clin Infect Dis. 2020 Sep 12;:
pubmed: 32918466
J Clin Virol. 2020 Aug;129:104544
pubmed: 32663788
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Am J Clin Pathol. 2020 Aug 5;154(3):293-304
pubmed: 32583852
J Clin Virol. 2020 Sep;130:104569
pubmed: 32769023
J Clin Virol. 2020 Dec;133:104663
pubmed: 33161369
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Clin Infect Dis. 2021 Aug 2;73(3):e699-e709
pubmed: 33400782
Diagnostics (Basel). 2020 May 19;10(5):
pubmed: 32438677
J Med Virol. 2021 Apr;93(4):2227-2233
pubmed: 33135795